Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11520 posts found.

lynparza

Europe approves Lynparza in HER2-, gBRCAm advanced breast cancer

April 10, 2019 Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, breast cancer, lynparza, pharma

Lynparza (olparib), the poly ADP ribose polymerase (PARP) inhibitor developed by AstraZeneca and MSD, has been awarded marketing approval by …
News
shutterstock_57369385

Epilepsy Society calls for review of UK supply chain following “steep rise” in access issues

April 9, 2019 Manufacturing and Production, Sales and Marketing Epilepsy Society, UK, brexit, epilepsy, market access, pharma

The Epilepsy Society has drawn attention to the “steep rise” in UK patients who are encountering difficulty in accessing seizure …
News
shutterstock_349943306

FDA refuses to review Zogenix’s Fintepla in Dravet syndrome, shares tumble 30%

April 9, 2019 Manufacturing and Production, Sales and Marketing Dravet Syndrome, FDA, Fintepla, Zogenix

California-based biopharma firm Zogenix has been left frustrated after it received a correspondence from the FDA noting its refusal to …
News

Eisai and MSD’s Lenvima recommended for NHS Scotland in advanced or unresectable liver cancer

April 8, 2019 Manufacturing and Production, Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, liver cancer, pharma

Patients in Scotland with with advanced or unresectable hepatocellular carcinoma (HCC) will now be able to access Eisai and MSD’s …
News
simon-sturge-kymab-tile

Kymab announces Merck exec Simon Sturge as new CEO

April 8, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, appointment, kymab, pharma

UK-based biotech Kymab has identified Merck KGaA executive Simon Sturge as its new Chief Executive Officer, taking over the reins …
Appointment
real_world

Protecting public health: Is real-world evidence the key?

April 8, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing feature, pharma, real world data, real world evidence, real-world data, real-world evidence

In often tough regulatory climates and with threats to public health are growing in sceptical corners of society, the need …
Feature

NICE turns down Astellas’ Xtandi in prostate cancer

April 8, 2019 Research and Development, Sales and Marketing Astellas, Cancer, NHS, NICE, UK, pharma, prostate cancer

Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for …
News
shutterstock_159488225

Alnylam and Sanofi close research phase of 2014’s $700m RNAi rare disease partnership

April 8, 2019 Research and Development, Sales and Marketing Alnylam, Genzyme, Sanofi, pharma, rare disease

Alnylam and Sanofi have announced their intention to bring to an end the research and option phase of a $700 …
News
x_ray_health_arm_doctors_medicine_bone_hospital_medical_insurance-480473

Osteoporisis risk in over half of European women over 70, three-quarters not treated, Amgen study finds

April 8, 2019 Research and Development, Sales and Marketing Amgen, Europe, UK, bones, osteoporosis, pharma, real world data, real-world data

A new study from Amgen analysing real-world data has revealed that more than half of European women over 70 years …
News
johnson_and_johnson_jj

€100m expansion of J&J’s Limerick manufacturing facility to bring up to 300 jobs

April 8, 2019 Manufacturing and Production, Sales and Marketing

Johnson & Johnson has revealed plans to expand its existing Vision Care facilities at the National Technology Park in Limerick, …
News
shutterstock_243110086

Merrimack shuts down development of investigational cancer drug, staff cuts to follow

April 8, 2019 Research and Development, Sales and Marketing cacner, merrimack, oncology, pharma

Merrimack Pharmaceuticals has taken the decision to terminate development of its antibody-directed nanotherapeutic cancer therapy MM-310 in the treatment of …
News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

April 5, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, Northern Ireland, Novartis, Placebo, UK, brexit, pharma

As Brexit looms, pharma trade lobby the ABPI called for a ban on exports of medicines in the case of …
News

FDA approves Pfizer’s Ibrance for advanced male breast cancer

April 5, 2019 Medical Communications, Sales and Marketing Cancer, FDA, Pfizer, breast cancer, ibrance, male breast cancer, pharma

The FDA has chosen to expand the indications of Pfizer’s Ibrance (palbociclib), the company announced, approving the CDK4/6 inhibitor in …
News

BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund

April 5, 2019 Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, Kidney cancer, NICE, UK, Yervoy, opdivo

NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to …
News
theo_harold

Crescendo Biologics selects current CFO Theodora Harold as new CEO

April 4, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Cambridge, Crescendo Biologics, Dr Peter Pack, Theo Harold, cfo

Cambridge, UK-based Crescendo Biologics have said current Chief Financial Officer (CFO) Theodora Harold will take over from Dr Peter Pack …
Appointment
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025